3. Drug Discovery for Neglected Diseases: View of A Public–Private Partnership

  1. Prof. Dr. Paul M. Selzer
  1. Rob Don and
  2. Eric Chatelain

Published Online: 28 JUL 2009

DOI: 10.1002/9783527626816.ch3

Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates

Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates

How to Cite

Don, R. and Chatelain, E. (2009) Drug Discovery for Neglected Diseases: View of A Public–Private Partnership, in Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed P. M. Selzer), Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany. doi: 10.1002/9783527626816.ch3

Editor Information

  1. BioChemInformatics, Intervet Innovation GmbH, Zur Propstei, 55270 Schwabenheim, Germany

Author Information

  1. Drugs for Neglected Diseases Initiative (DNDi), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland

Publication History

  1. Published Online: 28 JUL 2009
  2. Published Print: 22 APR 2009

ISBN Information

Print ISBN: 9783527323272

Online ISBN: 9783527626816

SEARCH

Keywords:

  • chagas' disease;
  • drug discovery;
  • human african trypanosomiasis;
  • lead optimization;
  • neglected diseases;
  • product-development partnership;
  • visceral leishmaniasis

Summary

This chapter contains sections titled:

  • Introduction

  • Public–Private Partnerships

  • Human African Trypanosomiasis (HAT)

  • Lead Optimization at DNDi: Building the Pipeline

  • Lead Optimization at DNDi: Supporting the Pipeline

  • Lead Optimization at DNDi: Feeding the Pipeline

  • Conclusion

  • References